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Objective: Hypertensive patients have higher mortality rates from hemorrhagic shock (HS) than normo-
tensive patients. HS can produce several proinﬂammatory mediators such as tumor necrosis factor alpha
(TNF-a) and interleukin 6 (IL-6), leading tomultiple organ dysfunction and death. Erythropoietin (EPO) has
pleiotropic cytoprotective actions. We investigated the effects of EPO (300 U/kg) treatment on HS-induced
serum proinﬂammatory cytokines and biochemical changes in spontaneously hypertensive rats (SHRs).
Materials and Methods: Severe HS was induced by withdrawing 60% of the rat’s total blood volume via
a femoral arterial catheter (6 mL/100 g body weight) over 30 minutes. The mean arterial pressure (MAP)
and heart rate (HR) were monitored continuously for 2 hours after the start of blood withdrawal. Levels
of biochemical and cytokine parameters, including glutamic oxaloacetic transaminase (GOT), glutamic
pyruvic transaminase (GPT), blood urea nitrogen (BUN), creatinine (Cre), creatine phosphokinase (CPK),
lactate, TNF-a, and IL-6 were measured 1 hour after HS had been induced.
Results: HS signiﬁcantly increased HR and blood GOT, GPT, BUN, Cre, CPK, lactate, TNF-a, and IL-6 levels,
and decreased hemoglobin level and MAP, in SHRs. Pretreatment with EPO improved the survival rate at
2 hours, preserved the MAP, decreased tachycardia and markers of organ injury (GOT, GPT, BUN, Cre, CPK,
lactate), and suppressed the release of TNF-a and IL-6 after HS in SHRs.
Conclusion: Pretreatment with EPO suppresses the release of serum TNF-a and IL-6, and decreases the
levels of markers of organ injury associated with HS in SHRs.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Hemorrhagic shock (HS) leads to hemodynamic instability,
decreases tissue perfusion, and causes cellular hypoxia, organ
damage, and death [1,2]. After HS, nuclear factor kappa kB (NF-kB)
is involved and further increases the inﬂammatory cascade [3,4].
Overwhelming production of proinﬂammatory cytokines such as
tumor necrosis factor alpha (TNF-a) and interleukin 6 (IL-6) leads to
multiple organ dysfunction and death after HS [5].
Erythropoietin (EPO) has been found to interact with its
receptor in a large variety of non-hematopoietic tissues to inducey, Buddhist Tzu Chi General
aiwan. Tel.: þ886 3 8561825;
).
ddhist Compassion Relief Tzu Chicytoprotective responses [6e8]. EPO promotes the degradation to
inhibitory kB (IkB), further decreases NF-kB, and decreases proin-
ﬂammatory cytokine production after HS [9]. Hypertensive patients
have a higher mortality rate from hemorrhage after trauma than
normotensive patients [10,11]. In the present study, we examined
the effects of pretreatment with EPO on cytokines induced by
severe HS (TNF-a and IL-6) and organ damage in conscious spon-
taneously hypertensive rats (SHRs).2. Materials and methods
2.1. Preparation of animals
Twenty-four male SHRs weighing 250e300 g were purchased
from the National Animal Center (Taipei, Taiwan). They wereFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A) Two-hour survival rates for spontaneously hypertensive rats during severe
hemorrhagic shock (HS). (B) Change in hemoglobin level after HS in spontaneously
hypertensive rats. *p< 0.05 for the HS group compared with the control group.
#p< 0.05 for the erythropoietin (EPO)þHS group compared with the HS group.
R.-P. Lee et al. / Tzu Chi Medical Journal 24 (2012) 46e50 47housed in the university Animal Center in a controlled environment
at a temperature of 221C with a 12-hour light/dark cycle. Food
and water were provided ad libitum. The Animal Care and Use
Committee of Tzu Chi University approved the experimental
protocol.
The animals were anesthetized with ether inhalation for about
15 minutes. During the period of anesthesia, a femoral artery was
cannulated and connected to a pressure transducer (Gould Instru-
ments Systems Inc, Cleveland, OH, USA) to record arterial pressure
and heart rate (HR) on a polygraph recorder (PowerLab; ADIn-
struments, Mountain View, CA, USA). A femoral vein was cathe-
terized for intravenous administration of drugs or ﬂuid. The
operationwas completedwithin 15minutes, leaving a small section
wound (less than 0.5 cm2). After the operation, the animals were
placed in a metabolic cage (Shingshieying Instruments, Hualien,
Taiwan). The rats soon awakened after the operation [12e14].
2.2. Hemorrhagic shock
HS was induced 24 hours later after the operation. HS was
induced by drawing blood from the femoral arterial catheter into
a 10 mL syringe. An infusion pump controlled the withdrawal rate
to mimic a typical bleeding event. The blood volume withdrawn
was 60% of the total blood volume (6 mL/100 g body weight)
[15,16]. The duration of blood withdrawal was 30 minutes. Normal
saline 0.5 mL was infused as ﬂuid resuscitation at 30 minutes
before induction of HS, and at 0, 1, and 2 hours after the start or end
of blood withdrawal. After blood withdrawal, the animals were
continuously observed for 2 hours [12e14].
2.3. Experimental design
The animals were randomly divided into three groups. Rats in
the control group (n¼ 8), were given 300 U/kg EPO (Roche, Man-
nheim, Germany) in 0.5 mL normal saline intravenously over 10
minutes and were not subjected to HS [13,17]. Rats in the HS group
(n¼ 8), were given 0.5 mL of an intravenous drip of normal saline
over 10 minutes, and then HS was induced. In the EPOþHS group
(n¼ 8), rats received 300 U/kg EPO in 0.5 mL normal saline intra-
venously over 10 minutes, after which HS was induced.
2.4. Blood sample analysis
Blood samples (0.5 mL) were collected for measurement of
glutamic oxaloacetic transaminase (GOT), glutamic pyruvic trans-
aminase (GPT), blood urea nitrogen (BUN), creatinine (Cre), crea-
tine phosphokinase (CPK), and lactate at 1 hour after the start and
end of blood withdrawal.
Blood samples of about 0.1 mL for hemoglobin tests (Sysmex K-
1000; Sysmex America Inc, Mundelein, IL, USA) and 0.4 mL for the
other tests were immediately centrifuged at 3000 g for 10 minutes.
The serum was decanted and separated into two parts; one part
was stored at 4C within 1 hour after collection for biochemical
analysis. Serum levels of GOT, GPT, BUN, Cre, CPK, and lactate were
measured with an autoanalyzer (COBAS Integra C111; Roche Diag-
nostics, Basel, Switzerland) to obtain various biochemical data.
Another portion of the serum collected at 1 hour after HS was
stored at e80C for later measurement of TNF-a and IL-6 concen-
trations [12e14].
2.5. TNF-a and IL-6 measurements by ELISA
TNF-a and IL-6 concentrations in blood samples were measured
separately by antibody enzyme-linked immunosorbent assay
(ELISA) with a commercial antibody pair, recombinant standardand biotinestreptavidineperoxidase detection system (Endogen,
Rockford, IL, USA) as described previously [12e14]. Blood samples
were collected in serum-separated tubes. All reagents, samples, and
working standards were brought to room temperature and
prepared according to the manufacturer’s directions. Reactions
were quantiﬁed by optical density using an automated ELISA reader
(Sunrise; Tecan Co., Grödingen, Austria) at a wavelength of 450/
540 nm.
2.6. Data analysis
Data were expressed as mean standard error of the mean.
Statistical comparisons between different groups at corresponding
time points were made by repeated measures one- or two-way
analysis of variance followed by a post hoc test (Bonferroni’s
method). A value of p< 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Survival rate and hemoglobin
All rats had survived at 1 hour after HS. However, the survival
rate at 2 hours after induction of HS was 12.5% in the HS group,
100% in the control group, and 75% in the EPOþHS group (Fig. 1A).
The mortality rate in the EPOþHS group was signiﬁcantly lower
than in the HS group (#p< 0.05; Fig. 1A). The hemoglobin level was
decreased after induction of HS (Fig.1B). Pretreatment with EPO did
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the HS group after induction of HS (Fig. 1B).
3.2. Mean arterial pressure and heart rate
Mean arterial pressure (MAP) decreased rapidly after the
withdrawal of 60% of total blood volume from the femoral arterial
catheter in conscious SHRs (*p< 0.05; Fig. 2A). Pretreatment with
EPO increased MAP compared with that in the HS group at 1 hour
after HS (#p< 0.05;Fig. 2A). HRwas signiﬁcantly increased at 1 hour
after HS (*p< 0.05; Fig. 2B). Tachycardia decreased in the EPOþHS
group compared with the HS group at 1 hour after HS (#p< 0.05;
Fig. 2B).
3.3. GOT and GPT
GOT was increased at 1 hour after induction of HS in SHRs
(*p< 0.05; Fig. 3A). Pretreatment with EPO decreased GOT
compared with the HS group at 1 hour after induction of HS
(#p< 0.05; Fig. 3A). Serum GPT increased at 1 hour after HS
compared with the control group (* p< 0.05; Fig. 3B). Pretreatment
with EPO decreased GPT compared with the HS group at 1 hour in
SHRs (#p< 0.05; Fig. 3B).
3.4. BUN and Cre
HS increased blood BUN at 1 hour in SHRs compared with the
control group (*p< 0.05; Fig. 4A). Pretreatment with EPO decreasedFig. 2. Changes in (A) mean arterial pressure and (B) heart rate after hemorrhagic
shock (HS) in spontaneously hypertensive rats. *p< 0.05 for the HS group compared
with the control group. #p< 0.05 for the erythropoietin (EPO)þHS group compared
with the HS group.
Fig. 3. Changes in (A) serum glutamic oxaloacetic transaminase (GOT) and (B) serum
glutamic pyruvic transaminase (GPT) after hemorrhagic shock (HS) in spontaneously
hypertensive rats. *p< 0.05 for the HS group compared with the control group.
#p< 0.05 for the erythropoietin (EPO)þHS group compared with the HS group.BUN at 1 hour compared with the HS group (#p< 0.05; Fig. 4A).
Serum Cre increased at 1 hour after induction of HS compared with
the control group (*p< 0.05; Fig. 4B). Pretreatment with EPO
decreased serum Cre compared with the HS group at 1 hour after
HS in SHRs (#p< 0.05; Fig. 4B).3.5. CPK and lactate
Blood CPK increased 1 hour after induction of HS (Fig. 5A).
Pretreatment with EPO decreased CPK comparedwith the HS group
at 1 hour after induction of HS (#p< 0.05; Fig. 5A). Serum lactate
increased at 1 hour after HS compared with the control group
(*p< 0.05; Fig. 5B). Pretreatment with EPO decreased the serum
lactate compared with the HS group at 1 hour after HS (#p< 0.05;
Fig. 5B).3.6. TNF-a and interleukin-6
HS greatly elevated serum TNF-a compared with the control
group at 1 hour after induction of HS (*p< 0.05; Fig. 6A).
Pretreatment with EPO signiﬁcantly decreased serum TNF-a at 1
hour after induction of HS (#p< 0.05; Fig. 6A). HS increased serum
IL-6 compared with the control group at 1 hour after induction of
HS (*p< 0.05; Fig. 6B). EPO decreased serum IL-6 compared with
the HS group at 1 hour after induction of HS (#p< 0.05; Fig. 6B).
Fig. 4. Changes in (A) serum blood urea nitrogen (BUN) and (B) serum creatinine (Cre)
after hemorrhagic shock (HS) in spontaneously hypertensive rats. *p< 0.05 for the HS
group compared with the control group. #p< 0.05 for the erythropoietin (EPO)þHS
group compared with the HS group.
Fig. 5. Changes in serum (A) creatine phosphokinase (CPK) and (B) lactate after
hemorrhagic shock (HS) in spontaneously hypertensive rats. *p< 0.05 for the HS group
compared with the control group. #p< 0.05 for the erythropoietin (EPO)þHS group
compared with the HS group.
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This study found that pretreatment of test rats with EPO
improved survival, decreased hypotension after induction of
hemorrhage and ameliorated severe HS-induced organ damage
(GOT, GPT, BUN, Cre, CPK, lactate) and possible effects by decreasing
serum TNF-a, IL-6 levels in SHRs.
Hypertensive patients have a higher mortality rate fromHS than
normotensive individuals [10,11]. Endothelial cell damage, accu-
mulation of leukocytes, disseminated intravascular coagulation,
and microcirculatory dysfunction ﬁnally lead to programmed cell
death (apoptosis) and necrosis of parenchymal cells with the
development of multiple organ damage in HS [3].
Endothelial dysfunction in conduit and resistance arteries is
common in SHRs [18]. EPO raises blood pressure in SHRs [19] and
stabilizes endothelial structures and vascular integrity such as
cellecell and cellematrix contacts, and is also a potent regulator of
proliferation and differentiation in endothelial progenitor cells
[20]. These actions show that endothelial progenitor cells have
vascular protection/repair properties through the mobilization
and recruitment of endothelial progenitor cells to sites of endo-
thelial injury [21].
A previous study noted that conscious SHRs had a higher
mortality rate than conscious Wistar-Kyoto rats after the samedegree of HS [12]. In this study, pretreatment with EPO improved
survival, and decreased hypotension and tachycardia, after induc-
tion of severe HS in conscious SHRs.
EPO has for nearly 20 years been widely used for the treatment
of anemia associated with chronic kidney disease and cancer
chemotherapy [9]. EPO and its receptor are widely expressed in
embryonic and adult tissues, including the liver and kidney [9,21].
EPO protects renal tissues from different models of acute renal
failure and ameliorates ischemia/reperfusion liver injury in rats
[22,23]. EPO has also been shown to improve liver and kidney
injury after HS in rats [17,24]. Our results show that treatment with
EPO reduced the severe HS-induced increases in serum GOT, GPT,
BUN, and Cre levels in SHRs.
Hyperlactatemia is a common complication during HS, and
serum lactate has been shown to be a predictor of the outcome of
HS [25,26]. Our results noted that hypotension and hyperlactatemia
were observed after severe HS in SHRs. The increase in serum
lactate generally originates from both increased lactate production
and decreased hepatic clearance [27]. The kidneys also contribute
to lactic acid removal [27]. It was found that EPO decreased severe
HS-induced liver and kidney damage, preserved blood pressure,
decreased lactic acid production, and increased the survival of SHRs
after HS.
Fig. 6. Changes in serum (A) tumor necrosis factor-a (TNF-a) and (B) interleukin-6 (IL-
6) after hemorrhagic shock (HS) in spontaneously hypertensive rats. *p< 0.05 for the
HS group compared with the control group. #p< 0.05 for the erythropoietin (EPO)þ
HS group compared with the HS group.
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inﬂammatory cascade, such as TNF-a and IL-6 levels [3,4]. TNF-
a and IL-6 have been shown to peak early after HS [12e14].
Treatment with monoclonal antibodies to TNF-a can reduce HS-
induced acute lung injury [28]. Moreover, administration of
recombinant IL-6 blunts lung mRNA levels of proinﬂammatory
cytokine TNF-a after HS in swine [29]. EPO promotes degradation of
IkB with subsequent translocation of NF-kB to the nucleus [9]. EPO
decreased TNF-a and IL-6 production in a chronic post-myocardial
infarction heart failure model in mice and a stroke model in rats
[30,31]. In this study, pretreatment with EPO reduced the severe
HS-induced serum TNF-a and IL-6 production. These results
suggest that EPO prevents HS-induced organ damage by decreasing
the production of proinﬂammatory cytokines and improves the
outcome after induction of HS in SHRs. Further studies are needed
to show the effects of EPO on HS.
In conclusion, pretreatment with EPO suppressed the release of
TNF-a and the production of IL-6, and decreased the levels of
markers of organ injury after induction of HS in conscious SHRs.
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